Dr. Kyriakie Sarafoglou, MD

Dr. Sarafoglou practices at M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview.

Dr. Sarafoglou's NPI, 1902989486, was assigned on October 20, 2006. Dr. Sarafoglou graduated from University of Athens in 1984. Dr. Sarafoglou holds Minnesota license 47368.

Dr. Sarafoglou's primary practice is M Health Fairview University of Minnesota Medical Center, at 2450 Riverside Avenue, Minneapolis, MN 55454 in Hennepin County. The practice phone is (612) 624-1765.

Dr. Sarafoglou's primary practice is M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview. The medical group on file is M Health Fairview Recovery Clinic. Dmand AI also links Dr. Sarafoglou to 4 more group practices and clinics, 4 medical groups and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sarafoglou practices, 6 sites in all. Vendor and product names are available with a free account.

Pediatrics is Dr. Sarafoglou's primary specialty in the NPI Registry, under taxonomy code 208000000X. Dr. Sarafoglou is board certified in pediatric endocrinology by the American Board of Pediatrics. Dr. Sarafoglou is licensed in Minnesota.

Dmand AI lists underactive thyroid among the conditions Dr. Sarafoglou treats.

Across all payers, Dmand AI patient panel data puts Dr. Sarafoglou's median patient age at 13, with 51% women.

In 2024, Dr. Sarafoglou wrote 81 Medicare Part D claims. 43% of them were for generic drugs. CMS names the drug for 64 of them, across 4 drugs with 11 or more claims each, at $1,408,369 in total drug cost. In 2023, CMS named 63 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Sarafoglou for performance year 2024, reported as part of a group. Dr. Sarafoglou accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 106 papers to Dr. Sarafoglou, published from 2008 to 2025. 2020 was the busiest year, with 10. The most frequent topics are Adrenal Hyperplasia, Congenital, Hydrocortisone and 17-alpha-Hydroxyprogesterone. Dr. Sarafoglou has published most often in J Clin Endocrinol Metab. Dr. Sarafoglou's most frequent co-authors are Bradley S. Miller, MD, Anna Petryk, MD and Richard J. Auchus, MD.

Dmand AI links Dr. Sarafoglou to 8 clinical trials, 4 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Adrenal Hyperplasia, Congenital, Adrenogenital Syndrome and Bone Resorption. Spruce Biosciences sponsors the most, 2.

CMS Open Payments shows 95 general payments to Dr. Sarafoglou from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 80% of the total. Neurocrine BioSciences, Inc. paid the most, $67,022. It also lists 19 research payments totaling $242,455 from 2024 to 2025.

Dr. Sarafoglou graduated from University of Athens in 1984. Dr. Sarafoglou is a member of ENDO.

Dr. Sarafoglou is in network with 17 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.